News

Unidym brings to this partnership its leadership in carbon nanotube science, technology and production. PrimeGen will have access to Unidym’s extensive patent portfolio, services and industry standard Hipco

This substantial award will fund the work necessary to bring the company’s neuropathic pain treatment, SCP-123, from the laboratory to the clinic, including the preparation of the investigational

In this study, 20 previously untreated elderly patients were treated with a novel combination of six cycles of CHOP chemotherapy followed by Zevalin given six to ten weeks

This positive opinion from the CHMP needs to be ratified by the European Commission in the coming months before final approval. The new 300mg tablet will facilitate the

The company said that Health Canada’s target is to complete review within 300 days for 90% of submissions. Vivian Liu, president and CEO of NexMed, said: “We are

The agreement includes the initial development and supply of quality control standards for 10 molecular targets that will be used in the development of Beckman Coulter’s molecular UniCel

Duramed’s Seasonique patent is due to expire on January 30, 2024. In addition to the patent, the company also has three-year new product exclusivity for its Seasonique product

The study (Res-05-0002) is a randomized, double-blind trial of reslizumab versus placebo in the treatment of pediatric patients between five and 18 years of age with poorly-controlled EE.

Under the terms of the agreement, Amgen will make an upfront payment to Kyowa Hakko of $100 million. Kyowa Hakko could receive up to $420 million in additional